All News

Found 7,634 articles

• Protalix Biotherapeutics, Inc. Announces New Strategy For Accelerated Growth

  1/5/2015

• Hospira, Inc. Receives U.S. FDA Approval Of Proprietary Analgesic Dyloject™(diclofenac sodium) Injection

  12/30/2014

• Palatin Technologies Announces Start Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction

  12/29/2014

• Hospira, Inc. Announces Voluntary Worldwide Recall Of 10 Lots Of Mitoxantrone Due To Confirmed Subpotency And Out-Of-Specification Impurities

  12/24/2014

• Baxter International, Inc. Submits Application For U.S. FDA Approval Of BAX111, Investigational Recombinant Treatment For Von Willebrand Disease

  12/22/2014

• Pfenex Inc. Announces Active IND And Additional BARDA Funding For Recombinant Anthrax Vaccine Program, Px563L

  12/22/2014

• Hospira, Inc. To Present At The J.P. Morgan 33rd Annual Healthcare Conference Jan. 14, 2015

  12/22/2014

• Creative Diagnostics Launches Improved Biosimilar Stable Cell line Products

  12/18/2014

• Apotex Inc. Announces FDA Has Accepted For Filing Its Biosimilar Application For Pegfilgrastim

  12/17/2014

• ImmunXperts Successfully Raises In Excess Of 1 Million USD In Equity And Bank Financing

  12/17/2014

• Actavis Will Appeal Injunction Requiring Continued Distribution Of NAMENDA IR

  12/16/2014

• Coherus Biosciences Reports Third Quarter 2014 Financial And Operating Results

  12/16/2014

• Actavis Announces Proposed Senior Leadership Team Effective Following Completion Of Allergan Acquisition

  12/16/2014

• Baxter International, Inc. To Divest Vero Cell Vaccines Platform To Nanotherapeutics

  12/15/2014

• Gene Therapy to Cure Blindness in 2015? Biotech Predictions Revealed

  12/12/2014

• Cipla Ltd. Sells Stake In Jiangsu Cdymax Pharma For $18.5 Million

  12/12/2014

• EPIRUS Biopharmaceuticals Seeks British Columbia Securities Commission Order That It Is No Longer A Reporting Issuer

  12/12/2014

• Zydus Cadila Launches World's First Biosimilar Of AbbVie's Humira In India

  12/9/2014

• Novartis AG Copy Of Amgen Cancer Drug Shows Similar Efficacy

  12/8/2014

• Phase 3 Data Shows Sandoz, Inc.'s Investigational Biosimilar Filgrastim Has Similar Safety And Efficacy As Amgen's NEUPOGEN®

  12/8/2014